344 related articles for article (PubMed ID: 33986322)
1. Bone loss in hepatitis B virus-infected patients can be associated with greater osteoclastic activity independently of the retroviral use.
Dessordi R; Watanabe LM; Guimarães MP; Romão EA; de Lourdes Candolo Martinelli A; de Carvalho Santana R; Navarro AM
Sci Rep; 2021 May; 11(1):10162. PubMed ID: 33986322
[TBL] [Abstract][Full Text] [Related]
2. Lamivudine, Entecavir, or Tenofovir Treatment of Hepatitis B Infection: Effects on Calcium, Phosphate, FGF23 and Indicators of Bone Metabolism.
Saeedi R; Mojebi-Mogharar A; Sandhu SK; Dubland JA; Ford JA; Yousefi M; Pudek M; Holmes DT; Erb SR; Peter Kwan W; Kendler DL; Yoshida EM
Ann Hepatol; 2017; 16(2):207-214. PubMed ID: 28233741
[TBL] [Abstract][Full Text] [Related]
3. Impact of antiretroviral therapy on bone metabolism markers in HIV-seropositive patients.
Marques de Menezes EG; de Paula FJ; Machado AA; de Assis Pereira F; Barbosa Júnior F; Navarro AM
Bone; 2013 Nov; 57(1):62-7. PubMed ID: 23891908
[TBL] [Abstract][Full Text] [Related]
4. Assessment of bone mineral density in patients with cirrhosis treated with third-generation nucleos(t)ide analogues: comparison between tenofovir and entecavir.
Tonon M; Piano S; Romano A; Fasolato S; Stanco M; Pilutti C; Pontisso P; Mareso S; Gambino C; Sartori L; Angeli P
Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):284-290. PubMed ID: 29309397
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection.
Ahn SH; Kim W; Jung YK; Yang JM; Jang JY; Kweon YO; Cho YK; Kim YJ; Hong GY; Kim DJ; Um SH; Sohn JH; Lee JW; Park SJ; Lee BS; Kim JH; Kim HS; Yoon SK; Kim MY; Yim HJ; Lee KS; Lim YS; Lee WS; Park NH; Jin SY; Kim KH; Choi W; Han KH
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1850-1859.e4. PubMed ID: 30448598
[TBL] [Abstract][Full Text] [Related]
6. Effects of Long-Term Tenofovir and Entecavir Treatment on Bone Mineral Density in Patients with Chronic Hepatitis B.
Kahraman R; Şahin A; Öztürk O; Çalhan T; Sayar S; Kanat E; Doğanay L; Özdil K
Turk J Gastroenterol; 2022 Jan; 33(1):35-43. PubMed ID: 35040786
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of bone mineral density and its influencing factors in 211 patients with chronic hepatitis B treated with long-term entecavir monotherapy].
Ning HB; Jin HM; Li K; Peng Z; Li W; Shang J
Zhonghua Gan Zang Bing Za Zhi; 2021 Mar; 29(3):234-239. PubMed ID: 33902190
[No Abstract] [Full Text] [Related]
8. Impact of hepatitis C virus infection on bone mineral density in renal transplant recipients.
Huang WH; Yu MC; Huang JY; Lai PC
PLoS One; 2013; 8(5):e63263. PubMed ID: 23675468
[TBL] [Abstract][Full Text] [Related]
9. Partial virological response to three different nucleotide analogues in naive patients with chronic hepatitis B.
Yegin EG; Ozdogan OC
Hepatobiliary Pancreat Dis Int; 2014 Dec; 13(6):602-11. PubMed ID: 25475862
[TBL] [Abstract][Full Text] [Related]
10. Sex steroids, biochemical markers, bone mineral density and histomorphometry in male osteoporosis patients.
Fassbender WJ; Balli M; Görtz B; Hinrichs B; Kaiser HE; Tracke HS
In Vivo; 2000; 14(5):611-8. PubMed ID: 11125545
[TBL] [Abstract][Full Text] [Related]
11. Three-year experience with risedronate therapy for patients with an increased fracture risk: assessment of proximal femoral bone density and geometry by DXA.
Takakuwa M; Iwamoto J; Itabashi K
Clin Drug Investig; 2012 Feb; 32(2):121-9. PubMed ID: 22185631
[TBL] [Abstract][Full Text] [Related]
12. High prevalence of reduced bone mineral density in primary HIV-1-infected men.
Grijsen ML; Vrouenraets SM; Steingrover R; Lips P; Reiss P; Wit FW; Prins JM
AIDS; 2010 Sep; 24(14):2233-8. PubMed ID: 20616695
[TBL] [Abstract][Full Text] [Related]
13. Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia.
Assoumou L; Katlama C; Viard JP; Bentata M; Simon A; Roux C; Kolta S; Costagliola D; Rozenberg S;
AIDS; 2013 Sep; 27(15):2425-30. PubMed ID: 24029735
[TBL] [Abstract][Full Text] [Related]
14. Bone mineral density of the spine and femur in healthy Saudi females: relation to vitamin D status, pregnancy, and lactation.
Ghannam NN; Hammami MM; Bakheet SM; Khan BA
Calcif Tissue Int; 1999 Jul; 65(1):23-8. PubMed ID: 10369729
[TBL] [Abstract][Full Text] [Related]
15. Influence of orlistat on bone turnover and body composition.
Gotfredsen A; Westergren Hendel H; Andersen T
Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1154-60. PubMed ID: 11486790
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance.
Lee S; Ahn SH; Jung KS; Kim DY; Kim BK; Kim SU; Baatarkhuu O; Ku HJ; Han K; Park JY
J Viral Hepat; 2017 Feb; 24(2):141-147. PubMed ID: 27766731
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
Gafni RI; Hazra R; Reynolds JC; Maldarelli F; Tullio AN; DeCarlo E; Worrell CJ; Flaherty JF; Yale K; Kearney BP; Zeichner SL
Pediatrics; 2006 Sep; 118(3):e711-8. PubMed ID: 16923923
[TBL] [Abstract][Full Text] [Related]
19. Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial.
Hoy JF; Grund B; Roediger M; Schwartz AV; Shepherd J; Avihingsanon A; Badal-Faesen S; de Wit S; Jacoby S; La Rosa A; Pujari S; Schechter M; White D; Engen NW; Ensrud K; Aagaard PD; Carr A;
J Bone Miner Res; 2017 Sep; 32(9):1945-1955. PubMed ID: 28650589
[TBL] [Abstract][Full Text] [Related]
20. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
Park JG; Park SY
Clin Mol Hepatol; 2015 Sep; 21(3):242-8. PubMed ID: 26523269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
